CD24 and neoplasm: Pre-clinically, neutralising anti-CD47 and anti-CD24 mAbs have demonstrated enhancement of non-specific macrophage phagocytosis of ovarian cancer cells in vitro, as well as inhibition of tumour growth in murine ovarian cancer models [102, 105].